```json
{
"content": [
{
"type": "paragraph",
"content": "North America dominates the Autoimmune Drugs market, capturing 35% of the global share. The region benefits from high adoption of advanced therapies, robust R&D investments, and a mature healthcare ecosystem. Policies supporting rapid drug approvals and strong payer coverage further accelerate market growth. Demographic trends, such as rising autoimmune disease prevalence, underpin sustained demand."
},
{
"type": "paragraph",
"content": "Europe follows with 30% market share, driven by policy frameworks promoting biosimilars, well-established healthcare infrastructure, and a skilled medical workforce. Aging populations and increasing awareness of autoimmune conditions are critical drivers. The region remains a regional forecast hotspot for innovation in biologics."
},
{
"type": "paragraph",
"content": Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12% (2024–2030). Key enablers include rising investments in healthcare infrastructure, growing middle-class adoption of premium therapies, and government initiatives to reduce disease burden. Demographics such as urbanization and lifestyle shifts are amplifying autoimmune disease prevalence."
},
{
"type": "paragraph",
"content": Latin America (8% share) and Middle East & Africa (2% share) lag but show potential. Policies like Brazil’s public health reforms and regional partnerships for autoimmune research are catalysts. However, infrastructure gaps and limited insurance coverage hinder broader Autoimmune Drugs market growth in these regions."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 35 },
{ "name": "Europe", "value": 30 },
{ "name": "Asia Pacific", "value": 25 },
{ "name": "Latin America", "value": 8 },
{ "name": "Middle East & Africa", "value": 2 }
]
}
}
```
